Gain Insight In To Viral Therapy Of Cancer

DUBLIN, Ireland--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/reports/c89124) has announced the
addition of "Viral Therapy of Cancer" to their offering.

In the last decade there has been an explosion of interest in
viral therapies for cancer. Viral agents have been developed that are
harmless to normal tissues but selectively able to kill cancer cells.
These agents have been endowed with additional selectivity and potency
through genetic manipulation. Increasingly these viruses are
undergoing evaluation in clinical trials, both as single agents and in
combination with standard chemotherapy and radiotherapy.

This book provides a comprehensive yet succinct overview of the
current status of viral therapy of cancer. Chapters coherently present
the advances made with individual agents and review the biological and
clinical background to a range of viral therapies: structured to
proceed from basic science at the bench to the patient's bedside, they
give an up-to-date and realistic evaluation of a therapy's potential
utility for the cancer patient.

- Presents state of the art knowledge on how viruses can be, and
have been, used in novel therapeutic approaches for the treatment of
cancer

- Describes the use of viruses as oncolytic agents, killing cells
directly

- Editors are experts in the field, with experience of both
laboratory and clinical research

Viral Therapy of Cancer is essential reading for both basic
scientists and clinicians with an interest in viral therapy and gene
therapy.

Topics Covered:

- Adenoviruses (Kate Relph, Kevin Harrington and Hardev Pandha).

- Application of HSV-1 factors to the treatment of cancer (Paola
Grandi, Kiflai Bein, Costas G. Hadjipanayis, Darren Wolfe, Xandra O.
Breakefield and Joseph C. Glorioso).

- Adeno-associated virus (Selvarangan Ponnazhagan).

- Retroviruses (Simon Chowdhury and Yasuhiro Ikeda).

-Lentiviral vectors for cancer gene therapy (Antonia Follenzi and
Elisa Vigna).

-Poxviruses as immunomodulatory cancer therapeutics (Kevin
Harrington, Hardev Pandha and Richard Vile).

-Oncolytic herpes simplex viruses (Guy R. Simpson and Robert S.
Coffin).

-Selective tumour cell cytotoxicity by reoviridae - preclinical
evidence and clinical trial results (Laura Vidal, Matt Coffey and
Johann de Bono).

-Oncolytic vaccinia (M. Firdos Ziauddin and David L. Bartlett).

- Newcastle Disease virus: a promising vector for viral therapy of
cancer (Volker Schirrmacher and Philippe Fournier).

-Vesicular stomatitis virus (John Bell, Kelly Parato and Harold
Atkins).

- Measles as an oncolytic virus (Adele Fielding .

- Alphaviruses (Ryuya Yamanaka).

- Tumour-suppressor gene therapy (Bingliang Fang and Jack A.
Roth).

-Gene-directed enzyme prodrug therapy (Silke Schepelmann, Douglas
Hedley,

- Immunomodulatory gene therapy (Denise Boulanger and Andrew
Bateman).

- Antiangiogenic gene delivery (Anita T. Tandle and Steven K.
Libutti).

- Radiosensitization in viral gene therapy (Jula Veerapong, Kai A.
Bickenbach and

- Radioisotope delivery (Inge D.L. Peerlinck and Georges Vassaux).

For more information, visit
http://www.researchandmarkets.com/reports/c89124

Research and Markets
Laura Wood
Senior Manager
Fax: +353 1 4100 980
press@researchandmarkets.com

Copyright Business Wire 2008